The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was initiated in 2015. Its goal is to provide an international infrastructure that will enable type 1 diabetes primary prevention trials. These trials will be built around programs that identify infants with an elevated genetic predisposition for type 1 diabetes, and will aim to reduce the incidence of the beta-cell autoimmunity that precedes clinical diabetes in children.
Currently we run a trial for the early detection of an increased risk to develop type 1 diabetes and a prevention trial for children with an elevated risk in the following countries: Belgium, Germany, Poland, Sweden and United Kingdom.











First commercial for the Freder1k study

Here with our first commercial of the Freder1k study.

Oral insulin for prevention of type 1 therapy

This video explains the disease mechanisms of type 1 diabetes and the impact of an oral insulin therapy.

How to take oral insulin in a type 1 diabetes intervention study

Helpful tips and advice